24/7 Market News Snapshot 12 December, 2024 – Trevi Therapeutics, Inc. Common Stock (NASDAQ:TRVI)

December 12, 2024

DENVER, Colo., 12 December, 2024 (247marketnews.com) – (NASDAQ:TRVI) are discussed in this article.
Trevi Therapeutics, Inc. is experiencing a notable surge in trading activity, with shares climbing approximately 33.94% in pre-market trading, now priced at $3.335 compared to the previous close of $2.490. This increase is supported by a substantial trading volume of 2.09 million shares, indicating robust investor enthusiasm potentially linked to recent advancements in Trevi’s innovative therapies.

In addition to this market momentum, Trevi Therapeutics has made significant strides in its ongoing Phase 2b CORAL trial of Haduvio™ (oral nalbuphine ER), aimed at treating chronic cough associated with idiopathic pulmonary fibrosis (IPF). The trial has reached 75% of its enrollment goal of 160 participants, maintaining its original sample size after a successful analysis by an Independent Data Monitoring Committee confirmed the trial’s statistical assumptions.

Jennifer Good, President and CEO of Trevi Therapeutics, expressed her satisfaction with the trial’s progress, highlighting its alignment with previous findings that demonstrated strong efficacy in earlier trials. She emphasized the importance of these results, noting that Haduvio has the potential to become a first-in-class therapy for chronic cough in IPF patients, a demographic currently lacking approved treatment options.

The CORAL trial assesses the efficacy of Haduvio at three different dosages, with results anticipated in the first half of 2025. The primary objective is to measure changes in 24-hour cough frequency after six weeks of treatment. Chronic cough affects around 85% of IPF patients, significantly diminishing their quality of life, underscoring Trevi’s commitment to addressing this critical unmet medical need.

As Trevi continues to navigate its clinical developments, the market’s positive response reflects investor confidence in its potential to deliver meaningful therapeutic innovations for patients suffering from debilitating health conditions.

Related news for (TRVI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.